Transplacental passage of a nonionic contrast agent by Vanhaesebrouck, Piet et al.
ORIGINAL PAPER
Piet Vanhaesebrouck Æ Alain G. Verstraete
Claudine De Praeter Æ Koenraad Smets
Alexandra Zecic Æ Margarita Craen
Transplacental passage of a nonionic contrast agent
Received: 4 January 2005 / Accepted: 16 February 2005 / Published online: 30 March 2005
 Springer-Verlag 2005
Abstract We report the presence of iopromide in the
bowel and urine of a preterm infant, born 10 days after
intravenous administration of the nonionic monomer to
his mother. Excessive urinary iodine excretion and
borderline hyperthyrotropinaemia were observed in the
infant. Moreover, crossing of the fetal blood-brain
barrier was demonstrated by detection of the angio-
graphic material in CSF and thus direct fetal neurotoxic
eﬀects cannot be excluded. Conclusion: These widely
used contrast media may cross the placenta and accu-
mulate in various fetal tissues in signiﬁcant amounts
causing possible neonatal toxicity. Therefore the peri-
natal safety of these diagnostic agents should at least be
questioned.
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Introduction
Although the newer nonionic contrast media used for
conventional X-ray and MRI studies are well-tolerated
in humans, very little is known about placental transfer
and the possible eﬀects on the fetus [7]. In two animal
models no placental passage of nonionic compounds
could be detected [2,16]; however, animal studies are not
always predictive of human response and adequate, well-
controlled studies in humans have not been done. In one
recently published report, placental transfer of iohexol
(Omnipaque) within 24 h was demonstrated postnatally
by fetal gut opaciﬁcation in a human twin pregnancy
[13]. We report the presence of iopromide not only in the
bowel but also in urine and CSF together with transient
mild thyroid dysfunction in a preterm infant after
intravenous administration of the contrast medium to
the mother 10 days before birth.
Case report
An obese (body weight 107 kg) 26-year-old primipara
was transferred to the maternity ward at 27 weeks of
gestation because of threatening preterm labour. Toc-
olysis was initiated. Two days later, because of acute
dyspnoea and low oxygen saturation, the attendant
radiologist deemed the performance of pulmonary CT
angiography necessary to exclude pulmonary embolism.
A high dose of the nonionic, iodinated contrast medium
iopromide (200 ml Ultravist-370, Schering) was given
intravenously. No lung embolism could be detected. Ten
days after the CT angiogram, membranes ruptured
spontaneously and 1 h later a preterm boy was born
vaginally at 29 weeks’ gestation. Apgar scores were 7
and 9 at 1 and 5 min, respectively. Birth weight was
1491 g. The baby had only mild respiratory distress. No
goitre was observed. A plain abdominal X-ray ﬁlm
performed on day 1 showed intraluminal gastrointesti-
nal opaciﬁcations consistent with the presence of
radiographic contrast material. This unexpected ﬁnding
was conﬁrmed by a lateral view ﬁlm (Fig. 1). Convul-
sions or abnormal neurological behaviour were not
observed. The iopromide level was 0.13 ng/ml in a urine
sample on day 8. Iopromide concentration in CSF on
day 9 was 0.1 ng/ml. The contrast monomer was no
longer detectable in a urine sample on day 12. Iopromide
was determined in CSF and urine by a method modiﬁed
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from those of Hirsch et al. [10] and Putschew et al. [14].
Liver and renal function tests, ionogram, as well as
clotting screening tests were all normal. Urinary iodine
concentration on day 8 of life was 880 lg/l (normal
reference value <200 lg/l). Iodine containing solutions
were not used in the delivery room or during neonatal
care. Serum FT4 levels were 1.1 and 1.2 ng/dl on days 7
and 31 of life, respectively (reference range 0.9–1.7 ng/
dl). The corresponding levels of TSH were 2.7 and
6.2 mU/l (95% age-speciﬁc conﬁdence intervals 0.45–
4.12 mU/l). Apart from a persistent apnoea syndrome,
the further hospital course was uneventful. On follow-up
at the corrected age of 4 months, the child showed
normal neurodevelopment, although some axial hyper-
extensive posturing was suspected. At that time, cerebral
ultrasound and thyroid function were normal (serum
FT4 1.3 ng/dl and TSH 2.3 mU/l).
Discussion
Transplacental passage and fetal uptake of an ionic
agent such as diatrizoate has been demonstrated in early
human pregnancy [5]. Neonatal intestinal opaciﬁcation
secondary to transplacental passage of an ionic contrast
medium (Renograﬁn-60) after maternal excretory urog-
raphy was ﬁrst documented by Kelleher et al. in 1979
[11].
In rodent and non-rodent animal models, nonionic
monomers such as iobitridol, iohexol and iopromide
administered in comparable doses as used clinically in
conventional X-ray imaging studies were shown to be
rapidly excreted with no clear passage across the pla-
centa and no retention in amniotic ﬂuid nor fetal tissues
[2,16]. However, one recent report documented placental
transfer of a nonionic contrast medium by the radio-
graphic appearance of contrast material in the intestines
of preterm twin fetuses after intravenous administration
of iohexol to the pregnant mother for angiography 17 h
before birth [13]. The present report conﬁrms the
transplacental passage of another nonionic monomer
administered to a pregnant mother 10 days before birth.
The contrast agent can pass across the placenta into the
fetal circulation, be excreted by the fetal kidneys into the
amniotic ﬂuid and can be swallowed by the fetus.
Alternatively, contrast medium from the maternal cir-
culation may equilibrate directly into the amniotic ﬂuid
by passive intramembranous diﬀusion and this ﬂuid is
then also swallowed by the fetus [9].
Iopromide is reported not to pass the blood-brain
barrier (Schering documentation); however, in our pa-
tient, iopromide could still be detected in CSF 20 days
after contrast administration to the mother. It is known
that intravascular contrast agents can occasionally cause
selective osmotic disruption of the blood-brain barrier
and may induce signs of direct neurotoxicity such as
transitory cortical blindness, convulsions, apnoea and
sedation [15]. Iopromide is not indicated for intrathecal
use. When the agent is given intrathecally, serious ad-
verse reactions have occurred, including death, convul-
sions, cerebral haemorrhage and coma [3].
Previous studies have shown that preterm infants are
very sensitive to an iodine load with a signiﬁcant risk of
hypothyroidism [12]. Ares et al. [1] reported that thyroid
complications due to iodine exposure should be sus-
pected in those premature infants with urinary iodine
concentrations greater than 200 lg/l. The iodine over-
load and mild, albeit transient, neonatal hyperthyro-
tropinaemia put our patient at risk of subclinical
hypothyroidism at a critical age for the normal devel-
opment of the nervous system in later infancy [4].
However, it is reassuring that (transient) hypothyroid-
ism or hyperthyrotropinaemia were not detected in the
patients of Dembinski et al. [6] receiving iopromide
postnatally for diagnostic imaging of non-radio-opaque
central silastic catheters. Degradation of iopromide
produces about 0.06 mg of free readily absorbable io-
dide per 100 ml contrast medium, which is signiﬁcantly
less than ionic and also most other nonionic agents. The
mother is also at risk for hypothyroidism due to the
Wolﬀ-Chaikoﬀ eﬀect (blockade of iodide absorption by
the thyroid gland) induced by the acute iodine overload.
Iodine-containing contrast media can induce transient
subclinical hypothyroidism in adult euthyroid patients
Fig. 1 Anteroposterior (A) and
lateral view (B) X-ray ﬁlms of
the abdomen on day 1 of life
showing the presence of
contrast material (arrows)
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[8]. Therefore our patient and his mother will be rou-
tinely monitored.
The potential hazards of fetal exposure to radio-
graphic non-ionic contrast agents should be further
investigated and for the time being their perinatal safety
should still be questioned. In the absence of speciﬁc
studies, it is recommended that when no safer alternative
exists, these products should be used very cautiously in
pregnant women.
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